These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 10846334)
1. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population. Rosing MA; Archbald CD J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):183-5. PubMed ID: 10846334 [TBL] [Abstract][Full Text] [Related]
2. Use of misoprostol for self-induced medical abortions among Saudi women: a call for attention. Alsibiani SA Gynecol Obstet Invest; 2014; 78(2):88-93. PubMed ID: 24993350 [TBL] [Abstract][Full Text] [Related]
3. Prevalence, attitudes and knowledge of misoprostol for self-induction of abortion in women presenting for abortion at Midwestern reproductive health clinics. Kerestes C; Sheets K; Stockdale CK; Hardy-Fairbanks AJ Sex Reprod Health Matters; 2019 Dec; 27(1):1571311. PubMed ID: 31533561 [TBL] [Abstract][Full Text] [Related]
4. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days. Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871 [TBL] [Abstract][Full Text] [Related]
5. In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. Elul B; Pearlman E; Sorhaindo A; Simonds W; Westhoff C J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):169-72. PubMed ID: 10846331 [TBL] [Abstract][Full Text] [Related]
6. Clinic-level introduction of medical abortion in Vietnam. Raghavan S; Ngoc Nt; Shochet T; Winikoff B Int J Gynaecol Obstet; 2012 Oct; 119(1):39-43. PubMed ID: 22877839 [TBL] [Abstract][Full Text] [Related]
7. Assessment of significant factors affecting acceptability of home administration of misoprostol for medical abortion. Kopp Kallner H; Fiala C; Gemzell-Danielsson K Contraception; 2012 Apr; 85(4):394-7. PubMed ID: 22067756 [TBL] [Abstract][Full Text] [Related]
8. Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria. Okonofua F; Shittu O; Shochet T; Diop A; Winikoff B Int J Gynaecol Obstet; 2014 Apr; 125(1):49-52. PubMed ID: 24507887 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City. Peña M; Dzuba IG; Smith PS; Mendoza LJ; Bousiéguez M; Martínez ML; Polanco RR; Villalón AE; Winikoff B Int J Gynaecol Obstet; 2014 Oct; 127(1):82-5. PubMed ID: 24957534 [TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion up to 13 weeks of gestation. Hamoda H; Ashok PW; Flett GM; Templeton A BJOG; 2005 Aug; 112(8):1102-8. PubMed ID: 16045525 [TBL] [Abstract][Full Text] [Related]
11. Regimens of misoprostol with mifepristone for early medical abortion: a randomised trial. Shannon C; Wiebe E; Jacot F; Guilbert E; Dunn S; Sheldon WR; Winikoff B BJOG; 2006 Jun; 113(6):621-8. PubMed ID: 16709204 [TBL] [Abstract][Full Text] [Related]
12. Early medical abortion in India: three studies and their implications for abortion services. Coyaji K J Am Med Womens Assoc (1972); 2000; 55(3 Suppl):191-4. PubMed ID: 10846337 [TBL] [Abstract][Full Text] [Related]
13. Acceptability and feasibility of medical abortion in Nepal. Karki C; Pokharel H; Kushwaha A; Manandhar D; Bracken H; Winikoff B Int J Gynaecol Obstet; 2009 Jul; 106(1):39-42. PubMed ID: 19345944 [TBL] [Abstract][Full Text] [Related]
14. Efficacy, acceptability and safety of medication abortion in low-income, urban Latina women. Teal SB; Harken T; Sheeder J; Westhoff C Contraception; 2009 Nov; 80(5):479-83. PubMed ID: 19835724 [TBL] [Abstract][Full Text] [Related]
15. Current medical abortion care. Creinin MD Curr Womens Health Rep; 2003 Dec; 3(6):461-9. PubMed ID: 14613667 [TBL] [Abstract][Full Text] [Related]
16. Feasibility, efficacy, safety, and acceptability of mifepristone-misoprostol for medical abortion in the Democratic People's Republic of Korea. Tran NT; Jang MC; Choe YS; Ko WS; Pyo HS; Kim OS Int J Gynaecol Obstet; 2010 Jun; 109(3):209-12. PubMed ID: 20206354 [TBL] [Abstract][Full Text] [Related]
17. Motivations for using misoprostol for abortion outside the formal healthcare system in Colombia: a qualitative study of women seeking postabortion care in Bogotá and the Coffee Axis. Ortiz J; Blades N; Prada E Reprod Health; 2024 Jun; 21(1):76. PubMed ID: 38824533 [TBL] [Abstract][Full Text] [Related]
18. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients]. Faucher P; Baunot N; Madelenat P Gynecol Obstet Fertil; 2005 Apr; 33(4):220-7. PubMed ID: 15894206 [TBL] [Abstract][Full Text] [Related]
19. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation. Hamoda H; Ashok PW; Flett GM; Templeton A Hum Reprod; 2005 Aug; 20(8):2348-54. PubMed ID: 15878927 [TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. Sanhueza Smith P; Peña M; Dzuba IG; García Martinez ML; Aranguré Peraza AG; Bousiéguez M; Shochet T; Winikoff B Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):75-82. PubMed ID: 25702071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]